What Johnson & Johnson and Eli Lilly are saying about Trump’s pharmaceutical tariffs, and Dexcom scores FDA approval for its glucose monitoring system.

President Donald Trump’s promise to impose tariffs on pharmaceutical imports is raising red flags among generic drugmakers and industry experts, who warn that such a move could lead to increased drug shortages and higher prices.

President Trump’s threatened tariffs could lead to higher out-of-pocket costs or insurance premiums, depending on whether drugmakers try to pass on the costs.